History of Raptor

  • September 2005: Raptor founded by former executives and scientists of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).
  • January 2006: Raptor purchases NeuroTrans™ program from BioMarin. NeuroTrans™ is being developed as a peptide-based drug transporter to cross the blood-brain barrier to treat neurodegenerative disorders.
  • May 2006: Raptor completes reverse merger with Highland Clan Creations Corp., an OTCBB company. Raptor management and Board of Directors assume leadership of merged public company (OTCBB: RPTP).
  • November 2006: Raptor executes worldwide exclusive license to Mesoderm development protein (Mesd), program for the potential treatment of breast cancer, from Washington University, St. Louis.
  • November 2006: Raptor initiates HepTide™ program, to deliver drugs to the liver for the potential treatment of primary liver cancer and other liver diseases.
  • October 2007: Raptor acquires intellectual property for the use of 4-methylpyrazole, for the potential treatment of ALDH2 deficiency, through its acquisition of Convivia, Inc.
  • December 2007: Raptor acquires exclusive worldwide license to delayed-release (DR) Cysteamine for the potential treatment of nephropathic cystinosis, Huntington’s Disease and other indications, through its acquisition of Encode Therapeutics.
  • February 2008: Raptor executes exclusive worldwide license to cysteamine, and related compounds, for the treatment of Non-alcoholic Steatohepatitis or NASH, from University of California, San Diego.
  • November 2008: Raptor reports positive results of Phase 2a clinical trial of Convivia for the potential treatment of acetaldehyde toxicity resulting from ALDH2 deficiency.
  • June 2009: Hoffman La-Roche exclusively licenses NeuroTrans™ program from Raptor.
  • September 2009: Raptor completes reverse merger with TorreyPines Therapeutics, Inc. (NASDAQ: TPTX). Raptor management and Board of Directors assume leadership of merged public company. Raptor trading begins on NASDAQ (NASDAQ: RPTP).
  • November 2009: Raptor reports positive results of Phase 2b clinical trial of DR Cysteamine (RP103) for the potential treatment of nephropathic cystinosis.
  • May 2010: Raptor reports positive results of Phase 2a clinical study of RP103 prototype for the potential treatment of NASH.
  • June 2010: Raptor acquires worldwide, exclusive license to patents from Weizmann Institute of Science and Niigata University, related to use of transglutaminase inhibitors for the potential treatment of Huntington’s Disease and other CNS disorders.
  • June 2010: Raptor licenses Convivia™ program to Uni Pharma Co., Ltd. for development and potential commercialization in Taiwan.
  • November 2010: Raptor reports Phase 2a clinical trial of RP103 for the potential treatment of Huntington’s Disease commences in France in collaboration with The Centre Hospitalier Universitaire d'Angers.
  • July 2011: Raptor announces its Phase 3 clinical trial of RP103 for nephropathic cystinosis meets its primary endpoint.
  • December 2011: Raptor announces the signing of a collaboration agreement with NIDDK, part of NIH, to conduct a phase 2b clinical trial in juveniles with NASH using RP104.
  • March 2012: Raptor applies for marketing approval of RP103 for the potential treatment of nephropathic cystinosis in the U.S. and E.U.

Successful Track Record

Raptor is a NASDAQ-listed biopharmaceutical company with a product pipeline that may advance therapeutic options for 8 different indications and includes potential for product launch within the next 12 months.